Tistoumab-Vedotin or Tiv-Dak is an antibody drug conjudate (ADC) targeting tissue factor which has shown clinical benefits in cervix cancer with possible cross over in vulvar cancer and similarly, TROP2 inhibitors, particularly ADCs like sacituzumab govitecan, are being investigated for cervical cancer treatment and may be an actionable agent in vulvar cancer management as well. This evidence concerns the gene TACSTD2 and cervical cancer.